Bayer didn’t start as a drug company. It started as a dye works.
Founded in 1863 by chemical salesman Friedrich Bayer and Johann Friedrich Weskott, who owned a dye manufacturing business, the German firm has undergone a radical transformation. Today, Bayer AG is a global entity with roughly 90,000 employees across more than 80 countries. Its revenue streams are split between pharmaceuticals, consumer health, and crop science.
But to understand how Bayer navigates today’s complex healthcare and agriculture markets, you have to look at its Bayer’s origins in chemical dye production and the accidental discovery that changed everything.
The Accidental Discovery That Launched a Brand
The company’s most famous product wasn’t planned. It was serendipity.
In 1899, Bayer chemist Felix Hoffmann synthesized acetylsalicylic acid. The world came to know it as aspirin. This wasn’t just another chemical compound. It became a household name and a cornerstone of modern pain relief.
Before aspirin, the firm was known as Friedr. Bayer et comp. It was based in Barmen (now Wuppertal) and focused on manufacturing dyestuffs. By 1881, it incorporated as Farbenfabriken vormals Friedr. Bayer & Co. The pivot to pharmaceuticals began in earnest around the time of aspirin’s launch.
Expansion and the Move to Leverkusen
The late 19th and early 20th centuries marked a shift from export-heavy dye sales to a more integrated international model.
Bayer established subsidiaries in the United States and across Europe. Revenue flowed from these exports, funding significant research and production capabilities. But location mattered.
In 1912, the company moved its headquarters to Leverkusen, near Cologne. This industrial site became the heart of its operations. It wasn’t just an administrative shift. It consolidated manufacturing and R&D under one roof, setting the stage for decades of growth.
“Bayer derived much of its early revenue from exports, relying on an international network before the World Wars reshaped global trade.”
Why Bayer’s Early Strategy Still Matters
You can’t separate Bayer’s current crop science division from its chemical roots. The expertise in synthetic chemistry developed for dyes and drugs laid the groundwork for modern agrochemicals.
The company’s ability to pivot from industrial chemicals to health solutions isn’t random. It’s a pattern.
- 1863: Founding as a dye manufacturer.
- 1899: Introduction of aspirin.
- 1912: Headquarters moved to Leverkusen.
This timeline shows a company constantly adapting. It started with color. It moved to chemistry. Then to biology. The mechanism of growth remains the same: research, synthesis, and global distribution.
Today’s debates about Bayer’s acquisition of Monsanto, its litigation surrounding Roundup, or its R&D pipeline in oncology are rooted in this history. The company that invented aspirin is the same one that now feeds billions and treats chronic diseases.
The shift from Barmen to Leverkusen wasn’t just about real estate. It was about scale. And that scale allowed Bayer to become the **B
The industrial heart of Bayer in Leverkusen started taking shape in the late 1800s. It wasn’t just a factory floor, though. Over the next few decades, it grew into the company’s central nervous system. By the early 20th century, this site was the headquarters for a growing chemical giant.
The IG Farben Consolidation
The trajectory changed sharply in 1912. Carl Duisberg took the helm as general director. He wasn’t just managing operations. He was pushing for a massive consolidation of Germany’s entire chemical sector. That pressure led to the creation of IG Farben in 1925.
Duisberg became the first chairman of this new cartel. Bayer didn’t break away. It stayed inside the structure. That structure held until the Allied authorities dissolved it in 1945. The war ended. The cartel was gone. Bayer was left with its assets and its reputation, but not its previous form.
Rebuilding and Diversification
It took six years for the company to stand on its own again. In 1951, Farbenfabriken Bayer Aktiengesellschaft was reestablished. The name felt clunky. It stuck until 1972, when the company adopted the simple Bayer name we recognize today.
The post-war era wasn’t just about survival. It was about diversification. From 1981 to 1999, Bayer held a controlling interest in the Agfa-Gevaert Group. That was a German and Belgian producer. They made photographic equipment. They produced film. They also handled magnetic tape and photocopying machines. It was a different world than the chemicals of today.
Strategic Acquisitions and the Monsanto Deal
Bayer didn’t stop at photography. The company shifted focus toward pharmaceuticals and agriculture. In 2002, it established a dedicated crop science division. This was a strategic pivot toward food production and protection.
The moves got bigger. In 2006, Bayer acquired Schering AG. That was a German pharmaceutical firm. Schering was the largest maker of birth control pills at the time. It added significant weight to Bayer’s healthcare portfolio.
Then came the elephant in the room. In 2016, Bayer agreed to purchase Monsanto. The American agricultural producer was famous for Roundup. It was a glyphosate-based herbicide. The deal was valued at $63 billion. It closed in 2018. The acquisition was supposed to secure Bayer’s position in global agriculture. It didn’t quite work out that way.
The Cost of Glyphosate
The legal trouble started almost immediately. Shortly after the acquisition closed, a California jury found Monsanto liable. The lawsuit alleged that Roundup caused cancer. Specifically, it pointed to non-Hodgkin lymphoma. The market reacted fast. The prospect of extensive legal liabilities dragged down Bayer’s stock value.
The financial exposure was real. In 2020, the company agreed to pay more than $10 billion to settle thousands of claims. That was supposed to be a resolution. It wasn’t.
Legal challenges bled into the 2020s. Bayer faced tens of thousands of lawsuits. The company set aside billions of dollars for settlements and related costs. The liabilities weren’t a one-time event. They were a recurring drain.
In 2025, a U.S. jury awarded $2.1 billion in damages in a single case. It was one of the largest verdicts to date. The pattern is clear
The legal battle over Roundup’s cancer warnings didn’t just end with a courtroom argument. It ended with a shift in federal power. Bayer’s defense rested on a specific claim: federal pesticide law should override state lawsuits. The logic was simple. The U.S. Environmental Protection Agency (EPA) does not mandate a cancer warning on the label. If the federal government doesn’t require it, states shouldn’t be able to sue companies for failing to include it.
In 2026, the U.S. Supreme Court agreed. The ruling came down 7–2 in Bayer’s favor.
How Federal Preemption Blocks State Lawsuits
This decision wasn’t just a technical win. It was a massive disruption to pending litigation. The court held that federal law preempts those specific state-level claims. The effect was immediate. Thousands of cases were expected to be blocked.
The ruling drew a hard line. It stopped lawsuits based solely on the lack of a warning label. It did not close the door entirely. Plaintiffs could still pursue product-design lawsuits. The mechanism for those claims remains distinct from labeling disputes.
“The ruling leaves open other types of claims, such as product-design lawsuits.”
A History of Chemical Firsts
Bayer’s legal victories are just one chapter in a company defined by chemical innovation. The Bayer cross is a globally recognized trademark. It sits above a list of firsts that shaped modern industry.
Bayer didn’t just participate in the chemical boom. It initiated many of it.
- Heroin (1898): Bayer was the first to mass-produce it. It was sold as a pain and cough medication.
- Aspirin (1899): Bayer originated and first marketed the drug. It remains a staple household item.
- Prontosil (1935): This was the first sulfa drug. It marked an early entry into antibiotics.
- Polyurethane (1937): Developed as a base material. It became essential for synthetic foams, paints, adhesives, and fibers.
Scores of pharmaceuticals, dyes, acetates, synthetic rubbers, plastics, and insecticides were also first developed by the company. The list of chemicals Bayer created or popularized is extensive. It spans from consumer health to industrial materials.
The Supreme Court case focused on one specific product. But the company’s footprint is much broader. The legal precedent set in 2026 protects Bayer from labeling suits. It does not change the history of what they invented. Or the sheer volume of chemicals that continue to define their portfolio.
